Profile - Proprietary Pharmaceuticals
Business at a Glance
- Abbott holds leadership positions in a number of therapeutic areas, such as autoimmune diseases, HIV, cystic fibrosis and thyroid disease.
- Humira is the number-one global biologic therapy.
Advancing Pharmaceutical Pipeline
- Abbott has unique compounds in development, including treatments for highly prevalent conditions.
- Over the past several years, we’ve tripled the number of new molecular entities in our pipeline.
- Biologic assets now represent more than 30 percent of our pipeline.
Abbott’s pharmaceutical business has a portfolio of proprietary products that includes dozens of medicines to treat prevalent conditions such as autoimmune diseases, HIV, prostate cancer, Parkinson’s disease and many others. Our on-market portfolio, composed of primarily specialty care products, provides therapy to millions of patients worldwide.
Autoimmune diseases develop when underlying defects in the immune system lead the body to attack its own organs, tissues and cells. These 80 chronic illnesses occur in nearly every part of the body, from joints to skin to the gastrointestinal tract.
The use of biologics to treat autoimmune diseases continues to grow globally. Our leading biologic therapy, Humira, is approved to treat six autoimmune diseases, including moderate to severe rheumatoid arthritis, moderate to severe Crohn’s disease and moderate to severe chronic plaque psoriasis. It currently treats approximately 585,000 patients around the world, helping to provide some relief from these chronic conditions. Humira has the potential for strong future growth as it is being studied in six additional indications. We also are working on several product enhancements to improve the patient experience.
Beyond Humira, we have a number of market-leading products in our portfolio, including Kaletra and Norvir, our leading antiviral medicines that redefined the HIV treatment landscape; Synthroid, one of the most-widely prescribed products for hypothyroidism; Creon, the leading pancreatic enzyme therapy for exocrine pancreatic insufficiency due to cystic fibrosis and several other conditions; AndroGel, a testosterone replacement therapy for men; Lupron Depot, for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty; and Synagis, a product that protects at-risk infants from severe respiratory disease. Our lipid franchise includes Niaspan, TriCor and Trilipix.
Abbott also has a robust pipeline with a number of medicines in development that have the potential to greatly improve patient care and provide future growth. Over the years, Abbott has supplemented its internal pipeline with external partnerships and collaborations. Our continued focus on key therapeutic areas and enhanced R&D productivity is yielding impressive results. Over the past several years, we’ve tripled the number of new molecular entities in our pipeline—and we have more than 20 compounds or indications currently in Phase 2 or Phase 3 development.
In our pharmaceutical pipeline, our goal is to develop innovative medicines that hold promise in difficult-to-treat diseases with a goal of bringing to market medicines that have strong clinical performance, patient benefit and economic value. We’re studying a variety of promising compounds in the areas of chronic kidney disease, neuroscience, oncology, virology, immunology and women’s health, among others.
Chronic Kidney Disease
Chronic kidney disease (CKD), the progressive loss of kidney function, affects millions of adults worldwide. CKD is on the rise, driven by higher rates of diabetes, obesity and hypertension. We have two compounds in development for CKD that have the potential to treat the disease and restore renal function.
We have multiple small molecules and biologics in human studies that target receptors in the brain that help regulate pain, mood, memory and other neurological functions. We are studying these compounds in a variety of conditions, including multiple sclerosis, Parkinson’s disease, schizophrenia, Alzheimer’s disease, and acute and chronic pain. Together, these conditions affect millions of people worldwide.
Cancer is a leading cause of death globally. We are investing in a number of cancer therapies that may change the way the disease behaves. Our mid-stage oncology pipeline features numerous compounds, including our PARP (Poly (ADP-ribose) polymerase) inhibitor and Bcl-2 protein inhibitors, which are being studied in various types of cancer.
The hepatitis C virus (HCV) affects 170 million people worldwide, with approximately 4 million patients newly diagnosed each year. HCV infections can potentially lead to long-term complications, including severe scarring of the liver, liver cancer or death. We have several compounds for HCV in development, including protease, non-nucleoside polymerase and NS5A inhibitors.
We’re leveraging our experience with Humira to identify new therapies with the potential to expand the treatment of an array of autoimmune diseases. Our immunology pipeline includes development work in oral disease-modifying therapies and biologics, as well as proprietary combination biologic agents.
We have a promising compound in development with a partner for endometriosis and uterine fibroids, both highly prevalent conditions associated with a number of symptoms including pain and infertility. Both of these conditions are undertreated and our treatment has the potential to fill a significant therapeutic void.